期刊文献+

GC-MS法测定磷酸西格列汀中磷酸三甲酯的含量 被引量:1

Determination of Trimethyl Phosphate in Sitagliptin Phosphate by GC-MS
原文传递
导出
摘要 建立了气相色谱-质谱(GC-MS)法测定磷酸西格列汀(1)中的基因毒性杂质磷酸三甲酯(3)。色谱柱选用DB-624(0.25 mm×30 m×1.4 μm)毛细管柱,采用选择离子监测(SIM)模式。结果显示,3在40.93~233.90 ng/ml内线性关系良好,定量限为40.9 ng/ml,检测限为12.3 ng/ml,平均加样回收率(n=12)为97.0%,RSD为5.2%,且稳定性良好。样品检测结果显示3批1中均未检出3,建立的分析方法重复性好、专属性强、灵敏度高,适用于1中基因毒性杂质3的检测。 A gas chromatography-mass spectrometry(GC-MS) method was established for the determination of the genotoxic impurity trimethyl phosphate(3) in sitagliptin phosphate(1).The DB-624(0.25 mm×30 m×1.4 μm) capillary column was used,and the selected ion monitoring(SIM) mode was adopted.The results showed that it was linear for 3 in the range of 40.93-233.90 ng/ml,the limit of quantification was 40.9 ng/ml,and the limit of detection was 12.3 ng/ml.The average sample recovery(n=12) was 97.0%,with the RSD of 5.2%,and the stability was good.The sample test results showed that 3 was not detected in three batches of 1.The established method has good repeatability,strong specificity and high sensitivity,which is suitable for the detection of genotoxic impurity 3 in 1.
作者 徐盼 董淑波 杨汉跃 李善金 程青芳 XU Pan;DONG Shubo;YANG Hanyue;LI Shanjin;CHENG Qingfang(School of Pharmacy,Jiangsu Ocean University,Lianyungang 222005;Jiangsu Deyuan Pharmaceutical Co.,Ltd.,Lianyungang 222047)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2022年第4期559-563,共5页 Chinese Journal of Pharmaceuticals
关键词 GC-MS 磷酸西格列汀 基因毒性杂质 磷酸三甲酯 GC-MS sitagliptin phosphate genotoxic impurity trimethyl phosphate
  • 相关文献

参考文献7

二级参考文献77

  • 1Dreher SD, Ikemoto N, Njolito E, et al. Process to chiral β-amino acid derivatives: WO, 2004085661 [P]. 2004-10-07. (CA 2004, 141: 332476).
  • 2Xiao Y, Armstrong JD, Krska S, et al. Process to chiral amino acid derivatives by asymmetric hydrogenation: WO, 200681151 [P]. 2006-08-03. (CA2006, 145: 189177).
  • 3Biflu T, Feng DD, Liang GB. 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: WO, 2004103276 [P]. 2004-12-02. (CA 2005, 142: 23098).
  • 4Hansen KB, Balsells J, Dreher S, et al. First generation process for the preparation of the DPP-IV inhibitor sitagliptin [J]. Org Process Res Dev, 2005, 9 (5) : 634-639.
  • 5Edmondson SD, Fisher MH, Kim D: Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: US, 6699871 [P]. 2004-03-02.
  • 6KimD, WangL, BeconiM, etal. (2R)-4-Oxo-4-[3- (trifluoromethyl) -5,6-dihydro [ 1,2,4] triazolo [4,3-a] pyrazin- 7 (8H) -y1] -1- (2,4,5- trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J]. J Med Chem, 2005, 48 (11): 141-151. (CA2005, 142: 198023).
  • 7Falchi A, Stivanello M, Serafini S. Process for the preparation of fluorophenylacetic acid and derivatives thereof: WO, 2008078350 [P]. 2008-07-03.
  • 8Perlman N, Etinger M, Niddam-Hildesheim V, et al. Preparation of 3 (R) -amino-4- (2,4,5-trifluorophenyl) butanoic acid esters as intermediates in synthesis of sitagliptin: WO, 2009064476 [P]. 2009-05-22. (CA 2009, 150: 515454).
  • 9ICH Q3A (R2), Impurities in New Drug Substances[ EB/OL]. (2006 - 10-25). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA422. pdf.
  • 10ICH Q3B (R2) Impurities in New Drug Substances [ EB/OL]. (2006 -06-02). [2014 -03 -31]. http://www, ich. org/ LOB/media/MEDIA421. pdf.

共引文献129

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部